This article is more than 5 years old. Information may no longer be current.

AHA announces late-breaking clinical trials for annual Scientific Sessions

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The American Heart Association has announced the line-up of late-breaking clinical trials slated for presentation at its annual Scientific Sessions in Chicago.

According to a press release, the meeting will feature four late-breaking clinical trial sessions comprising 16 studies on Nov. 16, 17, 18 and 19.

Highlights

Trials on the schedule include:

• IMPROVE-IT, a comparison of ezetimibe (Zetia, Merck) and simvastatin (Zocor, Merck) vs. simvastatin monotherapy on CV outcomes in patients with ACS.
• ODYSSEY-ALTERNATIVE, an assessment of the safety and efficacy of alirocumab (Sanofi/Regeneron) in statin-intolerant patients.
• INHERIT, an evaluation of losartan in patients with hypertrophic cardiomyopathy, and another study that will compare atenolol vs. losartan in children and young adults with Marfan syndrome.
• BASKET-PROVE II, a comparison of long-term outcomes with biodegradable vs. durable polymer drug-eluting stents and bare-metal stents.
• EVOLVE II, an evaluation of a novel bioabsorbable polymer-coated everolimus-eluting coronary stent.
• ISAR-SAFE, an assessment of 6 vs. 12 months of dual antiplatelet therapy after DES implantation.
• AVOID, a randomized controlled trial of oxygen therapy in patients with acute STEMI.
• Final results of the Mission: Lifeline STEMI ACCELERATOR study, a focus on the development of regional systems of care for STEMI.

Other sessions will include trials evaluating the risks and benefits of DAPT; risk for ischemic events following treatment discontinuation with prasugrel after DES implantation; CTA screening for asymptomatic, obstructive CAD in high-risk patients with diabetes; use of low-dose aspirin for prevention of CV-related events in elderly, at-risk patients; and more.

Visit Healio.com/Cardiology for more from the AHA Scientific Sessions

The Healio.com/Cardiology and Cardiology Today staff will provide live coverage of the Scientific Sessions, including the above late-breaking clinical trials and other research presented at the meeting, on-site video interviews with key experts and much more. Visit the website during the meeting and beyond for the latest news from this conference.